Bevacizumab in Recurrent Glioma: Patterns of Treatment Failure and Implications

Glioblastoma, the most common primary malignant brain tumor in adults, is highly aggressive and associated with a poor prognosis. Bevacizumab, a monoclonal antibody against the vascular endothelial growth factor receptor, has increasingly been used in the treatment of recurrent glioblastoma. It has...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yi, Ali, Saad, Clarke, Jennifer, Cha, Soonmee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Brain Tumor Society; The Korean Society for Neuro-Oncology; The Korean Society for Pediatric Neuro-Oncology 2017
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5433944/
https://www.ncbi.nlm.nih.gov/pubmed/28516072
http://dx.doi.org/10.14791/btrt.2017.5.1.1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5433944/
https://www.ncbi.nlm.nih.gov/pubmed/28516072
http://dx.doi.org/10.14791/btrt.2017.5.1.1

Ejemplares similares